SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing intense downward pressure driven by a mix of broader SaaS sector volatility and aggressive short-selling as investors debate the impact of AI competition on its long-term moat. While the community remains deeply divided between those viewing the current price as a deep-value buying opportunity and those fearing further dilution from upcoming lockup expirations and insider sales.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The iShares Expanded Tech-Software Sector ETF (IGV) is currently at the center of a heated debate over whether AI disruption via tools like Anthropic represents a fatal structural threat to legacy SaaS providers or a temporary, sentiment-driven repricing opportunity. Community members remain deeply divided between short-sellers anticipating a permanent valuation collapse and bulls who argue that major software incumbents are oversold and fundamentally resilient, leading to high-volume institutional buying and significant volatility.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a long-standing crypto joke that has evolved into an on-chain parody, drawing significant attention from community members who believe its deep history and meme status position it as a unique asset. Discussions are currently dominated by comparisons to Bitcoin's early days, debate over the project's legitimacy versus its satirical roots, and strong calls for community members to hold through volatility in hopes of long-term growth.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

The iShares Semiconductor ETF (SOXX) is currently at the center of a heated debate between retail traders who view it as an unstoppable "money machine" fueled by insatiable AI infrastructure demand and skeptics pointing to extreme valuation premiums and potential technical divergences. While bullish participants highlight the sector's leadership role and resilient price action, a vocal cohort of bears remains focused on the potential for a sharp correction as they monitor key support levels and signs of overextension.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys Inc. (ALOY) is trending as investors react to the company's recent capital raise and its strategic positioning as a domestic rare earth magnet supplier ahead of upcoming federal procurement restrictions on Chinese-sourced materials. While the community is actively debating the company's long-term potential in the defense supply chain, the stock has experienced significant volatility following the completion of its public offering.

Maulcoin

Maulcoin is trending as its community aggressively rallies to regain market momentum and push the ticker back onto major trading platforms. Supporters are actively engaging in social media raids and liquidity-focused community building to drive visibility for what they describe as a long-term, anti-rug project.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors capitalize on the successful Artemis II mission and growing anticipation for the company's expanded role in the lunar economy. The community is actively debating the stock's long-term potential as a space infrastructure leader, with many discussing the interplay between recent contract awards and high volatility.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant momentum driven by massive whale accumulation, liquidation of short positions, and speculative anticipation of major corporate partnerships. While bulls are focused on the token's potential within its decentralized event ecosystem, the community remains divided between those expecting further breakout rallies and skeptics warning of a potential correction due to incoming supply releases.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as a primary beneficiary of the AI infrastructure boom, with the community highlighting a strategic $2 billion investment and partnership with NVIDIA. Investors are actively discussing the company's critical role in optical interconnects and custom silicon, viewing its potential for massive revenue scaling as a key driver for long-term growth.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense community debate following an unexpected endorsement from President Trump, which has fueled a battle between retail bulls and short-sellers like Michael Burry. Traders are closely monitoring the stock's ability to hold critical support levels while reacting to concerns over potential competition from AI startups and the broader impact of political influence on market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN

Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE:BHVN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange...

Biohaven (NYSE:BHVN) Trading Down 5.3%  - Here's Why

Biohaven (NYSE:BHVN) Stock Price Down 5.3% - Time to Sell...

Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock

Citigroup boosted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a "buy" rating in a report on Thursday...

Biohaven (NYSE:BHVN) Shares Up 10.5% - Here's Why

Biohaven (NYSE:BHVN) Stock Price Up 10.5% - Still a Buy...

Biohaven (NYSE:BHVN) Trading 6.2% Higher - Here's Why

Biohaven (NYSE:BHVN) Trading Up 6.2% - What's Next...

JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN

JPMorgan Chase & Co. trimmed its position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 48.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,335,455 shares of the company's stock after selling 1...

Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have is...

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel...

TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00

TD Cowen upped their price objective on Biohaven from $15.00 to $30.00 and gave the stock a "buy" rating in a research note on Wednesday...

<ul class="summary-bullets"><li>Xenon plans to submit a new drug application for azetukalner to the U.S. Food and Drug Administration for the treatment of focal onset seizures in the third quarter of 2026.</li><li>CEO Ian Mortimer said that the trial results “exceeded expectations.”</li><li>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout.</li></ul><p><br>Xenon Pharmaceuticals Inc. (XENE) on Monday announced that it has commenced an underwritten public offering of $500 million of its common shares on the heels of the company announcing positive results from a trial of azetukalner in focal onset seizures (FOS).</p><p>The company said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to a placebo.</p><p>Shares of XENE closed 50% higher in the regular hours of trading.</p><h2 class="st-heading-2">Trial Data</h2><p>With the higher 25 mg dose, a 53.2% median percent change from baseline in monthly FOS frequency was observed, compared with 10.4% for the placebo, the company said.</p><p>Azetukalner also demonstrated a safety and tolerability profile consistent with prior studies, prompting the company to plan submitting a new drug application to the U.S. Food and Drug Administration (FDA) for the treatment of focal onset seizures in the third quarter of 2026.</p><p>CEO Ian Mortimer said that the trial results “exceeded expectations.”</p><p>“Epilepsy is one of the most common neurological diseases, and foundational antiseizure medications do not provide sufficient seizure control for up to 50% of patients, so we are very optimistic about the opportunity for azetukalner to meaningfully shift the epilepsy treatment paradigm,” said CMO Chris Kenney.</p><p>Focal onset seizures, or epilepsy, originate in one localized area of the brain, causing symptoms based on that specific region.</p><h2 class="st-heading-2">Wall Street Reaction</h2><p>Following the trial data announcement, several analysts hiked their price targets on the stock, while also reflecting on the news’ impact on the shares of Biohaven (<a href="https://stocktwits.com/symbol/BHVN">BHVN</a>), which is developing an investigational drug Opakalim for epilepsy, depression, and pain.</p><p>Jefferies raised the firm's price target on Xenon Pharmaceuticals to $100 from $65 and kept a ‘Buy’ rating on the shares. The firm said it thinks azetukalner has the attributes of a top-selling epilepsy pill, driven by best-in-class focal epilepsy data. In 2026, Xenon shares could grind higher as Big Pharma interest rises and as the Street gauges azetuklaner's peak sales potential, the analyst told investors in a research note.</p><p>RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $80 from $59 and kept an ‘Outperform’ rating on the shares, citing a belief that today's "strong" azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated and greater potential for the drug to be priced at a premium.</p><h2 class="st-heading-2">Biohaven Still Holds Chance</h2><p>Raymond James, meanwhile, kept a ‘Strong Buy’ rating on Biohaven shares following competitor Xenon’s data readout. Azetukalner showed efficacy in-line with expectations, but with a meaningful safety disadvantage, giving opakalim room to differentiate, it said. The firm believes the results continue to highlight an opportunity for opakalim, or BHV-7000, which has shown meaningful evidence of efficacy with better safety and tolerability.</p><p>Raymond James expects Biohaven to present topline results from the first pivotal trial for opakalim, testing a 25 mg and 50 mg dose, in the second half of 2026, which will more concretely establish the target product profile.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around XENE stock rose from ‘bullish’ to ‘extremely bullish’ over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.</p><p><a href="https://stocktwits.com/symbol/XENE">XENE stock</a> has gained 83% over the past 12 months.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/vrtx-soars-in-extended-hours-after-experimental-drug-shows-positive-changes-in-autoimmune-kidney-disease/cZdVDGuRIed">VRTX Soars In Extended Hours After Experimental Drug Shows Positive Changes In Autoimmune Kidney Disease</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Biohaven logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.

Equity

Xenon said that the late-stage study met its primary endpoint of median percent change from baseline in monthly FOS frequency to week 12 in both the 25 mg and 15 mg dose groups compared to placebo.


Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

BHVN
Biohaven Pharmaceutical Holding Company Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BHVN News

BHVNBiohaven Pharmaceutical Holding Company Ltd